Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

Pfizer

Status and phase: Completed; Phase 2

Conditions: Reduction in Severity of Skin Scarring

Treatments: Drug: EXC 001 (currently called PF-06473871)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01494922

B5301003

EXC 001-206

Details and patient eligibility

About

The purpose of this study is to provide subjects who participated in prior studies of EXC 001 the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.

Enrollment: 14 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Healthy adults who have participated in previous studies of EXC 001.
• Healthy adults who have chosen to have their scars revised.

Exclusion criteria

• Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or breast feeding.
• Participation in another clinical trial within 30 days prior to the start of the study.

Trial design

14 participants in 1 patient group

Open Label

Experimental group

Treatment:

Drug: EXC 001 (currently called PF-06473871)